Abstract
(Cancer Cell 35, 603–617.e1–e8; April 15, 2019) In the originally published version of this article, the labels in the lower left graph of Figure 6F “sgCHD1 EtOH” and “sgCHD1 DHT” were mistakenly swapped. In addition, the p value for difference between groups in Figure 6F was not described. The correct Figure 6F is now shown here and in the online version of the paper. The interpretation of the data and conclusions remain unaffected. The authors sincerely apologize for any confusion this error may have caused.Figure 6. AR Is Enriched at HOXB13 Sites in CHD1 Null Tumors (original)View Large Image Figure ViewerDownload Hi-res image Download (PPT) CHD1 Loss Alters AR Binding at Lineage-Specific Enhancers and Modulates Distinct Transcriptional Programs to Drive Prostate TumorigenesisAugello et al.Cancer CellMarch 28, 2019In BriefAugello et al. show that CHD1 binds prostate-specific enhancers enriched for the androgen receptor (AR). Upon CHD1 loss, which occurs often in prostate cancer (PCa), the AR cistrome changes to be consistent with that in PCa and is associated with an AR transcriptional signature unique to this subclass of PCa. Full-Text PDF Open Archive
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
